RLAY Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

12.570

Open

12.230

VWAP

12.10

Vol

2.30M

Mkt Cap

2.32B

Low

11.630

Amount

27.80M

EV/EBITDA(TTM)

Total Shares

191.59M

1.68B

EV/OCF(TTM)

P/S(TTM)

197.47

Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.

Events Timeline

(ET)

2026-05-19

06:20:00

Relay Therapeutics Releases zovegalisib Clinical Data, 60% of Patients Show Significant Improvement

2026-05-05 (ET)

2026-05-05

17:10:00

Relay Therapeutics Q1 Revenue $3M, Below Expectations

2026-04-27 (ET)

2026-04-27

06:10:00

Relay Therapeutics Advances Zovegalisib into Phase 3 Trials

News

9.0

13:10 PMstocktwits

Relay Therapeutics Reports Strong Early-Stage Data for Zovegalisib

9.0

12:04 PMNASDAQ.COM

Relay Therapeutics Reports Initial Clinical Results of Zovegalisib in Phase 2 Trial

9.0

11:11 AMseekingalpha

Relay Therapeutics' Zovegalisib Shows Promising Mid-Stage Trial Results

9.0

10:42 AMNewsfilter

Relay Therapeutics Reports Initial Clinical Data for Zovegalisib in Vascular Anomalies

9.5

05-04seekingalpha

Relay Therapeutics to Announce Q1 Earnings on May 5

9.0

04-27NASDAQ.COM

Relay Therapeutics Advances Zovegalisib into Phase 3 Trials for Breast Cancer

6 Analyst Rating

Wall Street analysts forecast RLAY stock price to rise

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

14.75

High

17.00

Current: 0.000

Low

13.00

Averages

14.75

High

17.00

H.C. Wainwright

NULL

Buy

maintain

$19 -> $25

AI Analysis

2026-04-29

Reason

H.C. Wainwright

Price Target

$19 -> $25

AI Analysis

2026-04-29

maintain

NULL

Buy

Reason

H.C. Wainwright raised the firm's price target on Relay Therapeutics to $25 from $19 and keeps a Buy rating on the shares. The firm says the Phase 1 zovegalisib triplet results "derisk" the planned Phase 3 trial.

Oppenheimer

Outperform

maintain

$14 -> $18

2026-04-28

Reason

Oppenheimer

Price Target

$14 -> $18

2026-04-28

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Relay Therapeutics to $18 from $14 and keeps an Outperform rating on the shares. The firm thought Relay's zovegalisib triplet data check an important box for the story, showing the drug can be safely dosed in a triplet combination without any drug-drug interactions. Broadly speaking, Oppenheimer believes the 44% ORR is competitive to gedatolisib's Phase 2 data - an admittedly high bar. Safety was strong without any Grade 3 hyperglycemia, which it thinks continues to validate the mutant-selective approach.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RLAY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Relay Therapeutics Inc (RLAY.O) is 0.00, compared to its 5-year average forward P/E of -5.45. For a more detailed relative valuation and DCF analysis to assess Relay Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.45

Current PE

0.00

Overvalued PE

-1.46

Undervalued PE

-9.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.28

Current EV/EBITDA

-4.20

Overvalued EV/EBITDA

0.31

Undervalued EV/EBITDA

-6.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

908.12

Current PS

118.86

Overvalued PS

2185.57

Undervalued PS

-369.33

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

most profit stock on Wednesday

Intellectia · 2823 candidates

Market Cap: >= 300.00MRegion: USPrice: >= $1.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000

Ticker

Name

Market Cap$

MOVE

Corvex, Inc

809.51M

CAR

Avis Budget Group Inc

9.01B

ALHC

Alignment Healthcare Inc

4.43B

ACIU

AC Immune SA

316.52M

ARMP

Armata Pharmaceuticals Inc

437.76M

OVID

Ovid Therapeutics Inc

386.63M

what are the biggest gainers today?

Intellectia · 98 candidates

Market Cap: >= 300.00MRegion: USPrice: >= $2.00Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

SGML

Sigma Lithium Corp

1.60B

AAOI

Applied Optoelectronics Inc

8.07B

KODK

Eastman Kodak Co

1.10B

ORIC

Oric Pharmaceuticals Inc

995.75M

SBAC

SBA Communications Corp

21.74B

SPIR

Spire Global Inc

557.03M

best day trade stock

Intellectia · 9 candidates

Price: $5.00 - $100.00Volume: >= 3,000,000Price Change Pct: >= $3.00Relative Vol: >= 2Beta: HighRisk

Ticker

Name

Market Cap$

KODK

Eastman Kodak Co

1.10B

ORIC

Oric Pharmaceuticals Inc

995.75M

LUNR

Intuitive Machines Inc

5.20B

RLAY

Relay Therapeutics Inc

2.24B

GSAT

Globalstar Inc

10.00B

AEHR

Aehr Test Systems

1.36B

todays top stocks

Intellectia · 47 candidates

Market Cap: >= 500.00MPrice: $2.00 - $500.00Volume: >= 300,000Price Change Pct: >= $7.00Relative Vol: >= 1.50

Ticker

Name

Market Cap$

SGML

Sigma Lithium Corp

1.32B

AAOI

Applied Optoelectronics Inc

6.71B

KODK

Eastman Kodak Co

911.63M

SBAC

SBA Communications Corp

18.28B

ORIC

Oric Pharmaceuticals Inc

1.42B

YSS

York Space Systems Inc

3.01B

what is the best stock to day trade today

Intellectia · 101 candidates

Price: $5.00 - $50.00Price Change Pct: >= $4.00Relative Vol: >= 2Gap Pattern: GapUpMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Franklin Covey Co

186.57M

KODK

Eastman Kodak Co

911.63M

SGML

Sigma Lithium Corp

1.32B

LUNR

Intuitive Machines Inc

4.39B

SATL

Satellogic Inc

816.86M

SPIR

Spire Global Inc

468.45M

todays top stocks to gain?

Intellectia · 57 candidates

Market Cap: >= 300.00MRegion: USPrice: $3.00 - $500.00Volume: >= 1,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

AAOI

Applied Optoelectronics Inc

6.33B

ARLO

Arlo Technologies Inc

1.68B

PRAA

PRA Group Inc

605.63M

FIGS

Figs Inc

2.57B

DELL

Dell Technologies Inc

98.13B

XRAY

DENTSPLY SIRONA Inc

2.93B

what are some good swing trades under $10

Intellectia · 69 candidates

Price: $1.00 - $10.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

GRNT

Granite Ridge Resources Inc

662.82M

PTEN

Patterson-UTI Energy Inc

3.07B

VVPR

VivoPower International PLC

40.97M

GXAI

Gaxos.ai Inc.

12.27M

Ampco-Pittsburgh Corp

158.34M

BRLS

Borealis Foods Inc

34.77M

biggest earners today

Intellectia · 14 candidates

Market Cap: >= 500.00MPrice: >= $3.00Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Richtech Robotics Inc

835.65M

RDW

Redwire Corp

1.79B

HUYA

HUYA Inc

846.71M

SATL

Satellogic Inc

592.67M

GLW

Corning Inc

81.28B

NET

Cloudflare Inc

66.96B

Whales Holding RLAY

TCG Crossover Management, LLC

Bellevue Asset Management AG

SB Investment Advisers (UK) Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Relay Therapeutics Inc (RLAY) stock price today?

The current price of RLAY is 12.1 USD — it has decreased -0.82

What is Relay Therapeutics Inc (RLAY)'s business?

What is the price predicton of RLAY Stock?

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is14.75 USD with a low forecast of 13.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

Relay Therapeutics Inc revenue for the last quarter amounts to 3.00M USD, decreased -60.93

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

Relay Therapeutics Inc. EPS for the last quarter amounts to -0.41 USD, decreased -10.87

How many employees does Relay Therapeutics Inc (RLAY). have?

Relay Therapeutics Inc (RLAY) has 192 emplpoyees as of May 19 2026.

What is Relay Therapeutics Inc (RLAY) market cap?

Today RLAY has the market capitalization of 2.32B USD.

RLAY Overview

RLAY Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding RLAY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Relay Therapeutics Inc (RLAY) stock price today?

What is Relay Therapeutics Inc (RLAY)'s business?

What is the price predicton of RLAY Stock?

What is Relay Therapeutics Inc (RLAY)'s revenue for the last quarter?

What is Relay Therapeutics Inc (RLAY)'s earnings per share (EPS) for the last quarter?

How many employees does Relay Therapeutics Inc (RLAY). have?

What is Relay Therapeutics Inc (RLAY) market cap?